Neurogene (NGNE) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free NGNE Stock Alerts $29.98 -0.66 (-2.15%) (As of 11:09 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:10 PM | markets.businessinsider.comBuy Rating Affirmed for Neurogene Amid Positive Outlook on NGN-401 and EXACT TechnologyMay 13 at 11:43 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Price Target Lowered to $51.00 at HC WainwrightHC Wainwright reduced their target price on Neurogene from $55.00 to $51.00 and set a "buy" rating on the stock in a report on Monday.May 13 at 2:18 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)May 11 at 1:54 AM | americanbankingnews.comWilliam Blair Analysts Boost Earnings Estimates for Neurogene Inc. (NASDAQ:NGNE)May 10, 2024 | investorplace.comNGNE Stock Earnings: Neurogene Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comNeurogene Inc. Q1 Loss Beats EstimatesMay 10, 2024 | washingtonpost.comNeurogene: Q1 Earnings SnapshotMay 10, 2024 | businesswire.comNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesMay 10, 2024 | marketbeat.comBrokers Issue Forecasts for Neurogene Inc.'s Q2 2024 Earnings (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - William Blair raised their Q2 2024 earnings per share estimates for Neurogene in a research note issued on Tuesday, May 7th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.89) for the quarter, up from tMay 10, 2024 | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Expected to Earn Q1 2025 Earnings of ($0.84) Per ShareMay 9, 2024 | marketbeat.comBrokers Set Expectations for Neurogene Inc.'s Q1 2025 Earnings (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a report issued on Tuesday, May 7th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($0.84) per share for the quarterMay 7, 2024 | americanbankingnews.comNeurogene (NASDAQ:NGNE) Stock Rating Reaffirmed by HC WainwrightMay 7, 2024 | businesswire.comNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingMay 4, 2024 | markets.businessinsider.comOptimistic Buy Rating for Neurogene’s NGN-401 Anticipating RMAT Designation and Promising Clinical DataMay 4, 2024 | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Receives $48.25 Consensus PT from BrokeragesMay 3, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Neurogene (NASDAQ:NGNE)HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Neurogene in a report on Friday.May 2, 2024 | marketbeat.comLeerink Partnrs Comments on Neurogene Inc.'s Q2 2024 Earnings (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2024 EPS estimates for shares of Neurogene in a research report issued to clients and investors on Monday, April 29th. Leerink Partnrs analyst M. Foroohar expects that the company will postMay 1, 2024 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Buy" from AnalystsShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokeMay 1, 2024 | marketbeat.comBrokers Set Expectations for Neurogene Inc.'s Q1 2024 Earnings (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Neurogene in a note issued to investors on Monday, April 29th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($1.19) for the quarter. LeerMay 1, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Rating Reaffirmed by Leerink PartnrsLeerink Partnrs reiterated an "outperform" rating on shares of Neurogene in a report on Monday.April 30, 2024 | nasdaq.comLeerink Partners Initiates Coverage of Neurogene (NGNE) with Outperform RecommendationApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene’s Promising Rett Syndrome Gene Therapy, NGN-401April 29, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB LeerinkSVB Leerink initiated coverage on Neurogene in a report on Monday. They set an "outperform" rating and a $46.00 price target on the stock.April 22, 2024 | businesswire.comNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingApril 19, 2024 | marketbeat.comWilliam Blair Weighs in on Neurogene Inc.'s Q1 2024 Earnings (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at William Blair lowered their Q1 2024 EPS estimates for shares of Neurogene in a report released on Wednesday, April 17th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.38)April 12, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Price Up 3.3%Neurogene (NASDAQ:NGNE) Trading Up 3.3%April 1, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Sees Unusually-High Trading VolumeNeurogene (NASDAQ:NGNE) Sees Unusually-High Trading VolumeMarch 26, 2024 | seekingalpha.comNeurogene Stock: Gene Therapy Specialist May Break Chain Of Failed MergersMarch 25, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Trading Up 5.2%Neurogene (NASDAQ:NGNE) Trading Up 5.2%March 21, 2024 | marketbeat.comWilliam Blair Initiates Coverage on Neurogene (NASDAQ:NGNE)William Blair assumed coverage on Neurogene in a research report on Thursday. They issued an "outperform" rating and a $61.00 price objective on the stock.March 21, 2024 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Expected to Post Q1 2024 Earnings of ($0.79) Per ShareNeurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2024 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Tuesday, March 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earningsMarch 20, 2024 | marketbeat.comNeurogene Inc. Expected to Earn FY2025 Earnings of ($4.15) Per Share (NASDAQ:NGNE)Neurogene Inc. (NASDAQ:NGNE - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings estimates for Neurogene in a research note issued on Tuesday, March 19th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($4.15) per share for the year. HC WainwrightMarch 20, 2024 | finance.yahoo.comNeurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023March 19, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)March 19, 2024 | finance.yahoo.comWith 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investorsMarch 19, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Given New $55.00 Price Target at HC WainwrightHC Wainwright lifted their price objective on shares of Neurogene from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday.March 18, 2024 | businesswire.comNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesMarch 5, 2024 | edition.cnn.comAkero Therapeutics, Inc.March 5, 2024 | marketbeat.comNeurogene's (NGNE) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of Neurogene in a research report on Tuesday.March 4, 2024 | finance.yahoo.comNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialMarch 1, 2024 | finance.yahoo.comNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerMarch 1, 2024 | finance.yahoo.comNeurogene to Participate in Upcoming Investor ConferencesDecember 19, 2023 | marketbeat.comTrading was temporarily halted for "NGNE" at 04:12 AM with a stated reason of "News pending." Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. NGNE Media Mentions By Week NGNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼0.700.57▲Average Medical News Sentiment NGNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼202▲NGNE Articles Average Week Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANL News TBPH News FULC News KRRO News PEPG News LXRX News TVTX News TRDA News BMEA News ANNX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
